LitCovid-sample-sentences  

PMC:7441788 / 15977-23287 JSONTXT 24 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T118 0-81 Sentence denotes Author (Reference) Study design Patients Treatment Outcomes Advantage Limitations
T119 82-97 Sentence denotes Gao et al [48].
T120 98-327 Sentence denotes Rough and simple description Not mentioned CQ (No specific dosage was mentioned) CQ was superior to control in suppressing pneumonia deterioration, improving lung imaging, promoting viral conversion and shortening disease course.
T121 328-344 Sentence denotes Not significant.
T122 345-471 Sentence denotes No study design and the specific number of patients and controls were provided and thus the result appears to be unconvincing.
T123 472-489 Sentence denotes Borba et al [49].
T124 490-976 Sentence denotes Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline
T125 977-1195 Sentence denotes Chen et al.[50] Randomized trial HCQ group: n = 31; control group: n = 30 HCQ (200 mg/2 times/day for 5 days) HCQ group have small improvement in body temperature and cough compered with control group Randomized trial.
T126 1196-1280 Sentence denotes Small sample size; Single-center design; Small improvement in temperature and cough.
T127 1281-1300 Sentence denotes Mahévas et al [53].
T128 1301-1519 Sentence denotes Comparative study HCQ group: n = 84; control group: n = 97 HCQ 600 mg/day for 7 days Compared with control group, a reduction of admissions to ICU or death 7 days after hospital admission was not observed in HCQ group.
T129 1520-1586 Sentence denotes Relatively larger sample size in HCQ treatment and control groups.
T130 1587-1697 Sentence denotes Nonrandomized design; In propensity score model, four possible important prognostic variables were unbalanced.
T131 1698-1714 Sentence denotes Tang et al [54].
T132 1715-1796 Sentence denotes Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80.
T133 1797-2003 Sentence denotes HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19.
T134 2004-2032 Sentence denotes Randomized controlled study.
T135 2033-2231 Sentence denotes Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased.
T136 2232-2415 Sentence denotes The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided.
T137 2416-2492 Sentence denotes The trial terminated early due to the difficulty to recruit enough patients.
T138 2493-2705 Sentence denotes Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results.
T139 2706-2725 Sentence denotes Geleris et al [55].
T140 2726-2969 Sentence denotes Observational study HCQ group: n = 811; no-HCQ group: n = 565 HCQ (600 mg/2 times on the first day, then 400 mg once a day for 4 days) No correlation between the HCQ use and significant higher or lower risk of intubation or death was observed.
T141 2970-3141 Sentence denotes Large sample size; Minimization of the unmeasured confusion and error through multivariable Cox model with inverse probability weighting according to the propensity score.
T142 3142-3251 Sentence denotes Single-center design; missing of some variables; Potential for inaccuracies in the electronic health records.
T143 3252-3266 Sentence denotes Yu et al [56].
T144 3267-3441 Sentence denotes Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group.
T145 3442-3570 Sentence denotes HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level.
T146 3571-3661 Sentence denotes Mortality was used as a measure of outcome and the study included critically ill patients.
T147 3662-3743 Sentence denotes Retrospective design of the study and the number of HCQ group patients was small.
T148 3744-4014 Sentence denotes Gautret et al.[57] Open label, nonrandom cohort study HCQ group: n = 12; HCQ＋azithromycin group: n = 6; control group: n = 12 HCQ (200 mg/3 times/day for 10 days) HCQ alone or in combination with azithromycin could effectively eliminate nasopharyngeal virus in 3–5 days.
T149 4015-4076 Sentence denotes Nasopharyngeal virus determination was used as main endpoint.
T150 4077-4226 Sentence denotes Small sample size; Six patients dropped out due to critical illness or intolerance to the drug; Lack of clinical outcomes; Limited follow-up results.
T151 4227-4246 Sentence denotes Gautret et al [58].
T152 4247-4490 Sentence denotes Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly.
T153 4491-4529 Sentence denotes Observation of nasopharynx viral load.
T154 4530-4614 Sentence denotes Observational study design and no control group; No clinical outcomes were analyzed.
T155 4615-4662 Sentence denotes Possible confounding factors were not adjusted.
T156 4663-4684 Sentence denotes Magagnoli et al [59].
T157 4685-4781 Sentence denotes Retrospective study HCQ group:n = 97HCQ＋azithromycin: n = 113No HCQ group:n = 158 Not specified.
T158 4782-5004 Sentence denotes The use of HCQ, either with or without azithromycin, didn’t reduce the risk of mechanical ventilation in patients hospitalized with COVID-19; Patients treated with HCQ alone was associated with increased overall mortality.
T159 5005-5226 Sentence denotes The study data comes from a comprehensive electronic medical record; Strictly defined covariates and outcomes; Using propensity scores adjustment for a large number of relevant confounders to make results more persuasive.
T160 5227-5420 Sentence denotes Retrospective nature of the study; The subjects included only men and most of them were black; Despite adjustments to many possible confounding factors, there may still be undiscovered factors.
T161 5421-5927 Sentence denotes Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality.
T162 5928-6010 Sentence denotes This study include a large, random sample from 25 metropolitan New York hospitals.
T163 6011-6175 Sentence denotes The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome.
T164 6176-6317 Sentence denotes Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders.
T165 6318-6397 Sentence denotes The dosing in the doses and frequencies of HCQ and azithromycin varied greatly.
T166 6398-6457 Sentence denotes The confidence intervals for some of the findings are wide.
T167 6458-6916 Sentence denotes Mehraet al[61] Multinational real-world analysis Teatment groups: n = 14,888Control group: n = 81,144 Mean daily dose: CQ 765 mg, (SD 308); HCQ 596 mg(126); CQ with a macrolide 790 mg(320); HCQ with a macrolide 597 mg(128).mean duration:CQ 6.6 days(2.4); HCQ 4.2 days(1.9);CQ with a macrolide 6.8 days(2.5); HCQ with a macrolide 4.3 days (2.0) A benefit of HCQ or CQ, when used alone or witha macrolide, on in-hospital outcomes for COVID-19 was not observed.
T168 6917-6991 Sentence denotes Large multinational real-world data and large number of study populations.
T169 6992-7310 Sentence denotes There may be potential confounders; It did not measure QT intervals and stratify the arrhythmia pattern; It did not determine whether the increased risk of death in-hospital and use of drug treatment regimens were directly related to cardiovascular risk; It did not observe the risk of the drug dose-response analysis.